Coxiella burnetii IgM Phase II ELISA Kit

Name: Coxiella burnetii IgM Phase II ELISA Kit
SKU: DEIA2186
Rating: 5 (1 reviews)

Regulatory status: For research use only, not for use in diagnostic procedures.

COA

SDS

Datasheet

Summary

Sample

serum, plasma

Species Reactivity

Human

Detection Method

iELISA

Intended Use

ELISA Coxiella burnetii Phase 2 IgM is qualitative test for detection of human antibodies in serum and plasma directed against Coxiella burnetii Phase 2. For sale in the U.S. for Research Use Only. Not for use in diagnostic procedures.

Contents of Kit

1. Break apart microtiter test strips each with 8 antigen coated single wells (altogether 96), 1 frame, the coating material is inactivated. 12
2. Positive control serum (ready-to-use), Human serum in phosphate buffer with protein; negative for anti-HIV, anti-HBs (Hepatitis B-Virus-surface antigen) and anti-HCV; preservative: < 0.1 % sodium azide, coloring: Amaranth O. 2 ml
3. Negative control serum (ready-to-use), Human serum in phosphate buffer with protein; negative for anti-HIV, anti-HBs (Hepatitis B-Virus-surface antigen) and anti-HCV; preservative: < 0.1 % sodium azide, coloring: Lissamin green V. 2 ml
4. Cut-off serum (ready-to-use), Human serum in phosphate buffer with protein; negative for anti HIV, anti-HBs (Hepatitis B-Virus-surface antigen) and anti-HCV; preservative: < 0.1 % sodium azide, coloring: Chinaldin yellow. 2 × 2 ml
5. Anti-human-IgM-conjugate (ready-to-use), Anti-human-IgM from goat (polyclonal), conjugated to alkaline phosphatase, stabilized with protein stabilization solution, preservative: 0.01 % methylisothiazolone, 0.01 % bromnitrodioxane. 13 ml
6. Washing solution concentrate (sufficient for 1 litre), Sodium chloride solution with Tween 20, 30 mM Tris, preservative: < 0.1 % sodium azide. 33.3 ml
7. Dilution buffer, Phosphate buffer with protein and Tween 20; preservative: < 0.1 % sodium azide, 0.01 g/l Bromphenol blue sodium salt. 2 × 50ml
8. Stopping solution, 1.2 N sodium hydroxide
9. Substrate (ready-to-use), Para-nitrophenylphosphate, solvent free buffer, preservative: < 0.1 % sodium azide. (Substrate in unopened bottle may have a slightly yellow coloring. This does not reduce the quality of the product!) 13 ml.

Storage

Reagent	Storage	Stability
microtiter strips (antigen)	after opening at 2-8°C in closed aluminum bag with desiccant. Strips which are not used must be stored in the press-seal bag of aluminum compound foil under dry and airtight conditions!	4 weeks
control sera / standard sera	after opening at 2-8°C	until expiry date; 24 months from date of production
conjugate	ready-to-use solution, at 2-8°C, Avoid contamination (sterile tips!)	until expiry date 28 months from date of production
washing solution	concentrate after opening at 2-8°C; working dilution at 2-8°C; working dilution at room temperature. Bottles used for the working dilution should be cleaned regularly, discard cloudy solutions.	until expiry date; 2 weeks; 1 week
substrate	ready-to-use solution at 2-8°C, protected from light! Avoid contamination (sterile tips!) Discard when solution turns yellow (extinction against distilled water > 0.25).	until expiry date 24 months from date of production
stopping solution	after opening at room temperature	until expiry date

General Description

The Q-fever zoonosis is a globally ubiquitous disease. Its pathogen is the Rickettsia Coxiella burnetii, a small, gram-negative, obligate intracellular bacterium.
Coxiella burnetii multiplies in the digestive system of ticks (Dermacentor marginatus in Germany) and in the trophoblasts of a host placenta. Accordingly, tick faeces and the afterbirth of infected mammals (predominantly sheep) are highly infectious. Therefore, occupational groups having direct contact with farm animals are at great risk of exposure. Infection usually results from inhalation of contaminated aerosols, especially during the dry summer months.
The incubation time for Q-fever is approximately 2-4 weeks following exposure. Influenzalike symptoms are often observed.
Diagnosis of Q-fever is currently based on serologic techniques. The use of ELISA test systems is recommended by the WHO because of high sensitivities and specificities and the ability to perform a differential analysis of the antibody response.

Citations